Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activities
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares OutstandingShares Outstanding
Ratios

Acro Biomedical (ACBM) Long-Term Debt Issuances (2017 - 2025)

Acro Biomedical has reported Long-Term Debt Issuances over the past 9 years, most recently at $25152.0 for Q4 2025.

  • Quarterly results put Long-Term Debt Issuances at $25152.0 for Q4 2025, up 144.43% from a year ago — trailing twelve months through Dec 2025 was $199924.0 (up 458.57% YoY), and the annual figure for FY2025 was $199924.0, up 443.39%.
  • Long-Term Debt Issuances for Q4 2025 was $25152.0 at Acro Biomedical, down from $58707.0 in the prior quarter.
  • Over the last five years, Long-Term Debt Issuances for ACBM hit a ceiling of $93759.0 in Q2 2025 and a floor of $36.0 in Q1 2023.
  • Median Long-Term Debt Issuances over the past 5 years was $6107.0 (2024), compared with a mean of $16170.6.
  • Biggest five-year swings in Long-Term Debt Issuances: plummeted 99.81% in 2023 and later surged 36811.11% in 2024.
  • Acro Biomedical's Long-Term Debt Issuances stood at $1091.0 in 2021, then plummeted by 78.74% to $232.0 in 2022, then surged by 4088.79% to $9718.0 in 2023, then rose by 5.89% to $10290.0 in 2024, then surged by 144.43% to $25152.0 in 2025.
  • The last three reported values for Long-Term Debt Issuances were $25152.0 (Q4 2025), $58707.0 (Q3 2025), and $93759.0 (Q2 2025) per Business Quant data.